Diethylcarbamazine

Summary

Diethylcarbamazine (CHEMBL684) is an approved small molecule (ATC P02CB02); indicated across 4 conditions including helminthiasis and filarial elephantiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02CB02
• Indications: 4 conditions
• Clinical trials: 17
• Chemistry: 199.29 Da · C10H21N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL684
Name	Diethylcarbamazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3052
ATC	P02CB02
Molecular formula	C10H21N3O
Molecular weight	199.29
InChIKey	RCKMWOKWVGPNJF-UHFFFAOYSA-N

SMILES: CCN(CC)C(=O)N1CCN(CC1)C

IUPAC name: N,N-diethyl-4-methylpiperazine-1-carboxamide

Also known as: Camin, Diethylcarbamazine, Dietilcarbamazina, DEC, N, Diethylcarbamzine, diethylcarbamazine, DIETHYLCARBAMAZINE, MMV002816, C0237398

Parent form; salt/anhydrous children: CHEMBL937

Patent coverage: 1,593 distinct patent families (6,192 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	5.28	AC50	5300	nM	CHEMBL_ACT_25165383

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
helminthiasis	4	MONDO:0004664	EFO:1001342
filarial elephantiasis	3	MONDO:0005761	EFO:0007272
loiasis	2	MONDO:0016566	EFO:1000729

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE2	6
Not specified	6
PHASE4	2
PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01593722	PHASE4	COMPLETED	Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
NCT02005653	PHASE4	COMPLETED	Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection
NCT07159373	PHASE3	NOT_YET_RECRUITING	Better Options for Lymphatic Filariasis Treatment
NCT04410406	PHASE3	COMPLETED	Moxidectin for LF, Cote d’Ivoire (DOLF)
NCT06070116	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
NCT00375583	PHASE2	COMPLETED	Effect of Albendazole Dose on Clearance of Filarial Worms
NCT00511004	PHASE2	COMPLETED	Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
NCT01111305	PHASE2	COMPLETED	Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
NCT01975441	PHASE2	COMPLETED	Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
NCT03664063	PHASE2	COMPLETED	PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
NCT05528354	EARLY_PHASE1	UNKNOWN	Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients
NCT00001230	Not specified	RECRUITING	Host Response to Infection and Treatment in Filarial Diseases
NCT07117422	Not specified	RECRUITING	Venetoclax-Decitabine in Untreated Elderly/Unfit AML
NCT00295698	Not specified	COMPLETED	Interaction Between HIV and Lymphatic Filariasis
NCT01905423	Not specified	COMPLETED	Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
NCT02974049	Not specified	COMPLETED	Lymphatic Filariasis (LF) in Ivory Coast
NCT05091385	Not specified	COMPLETED	Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).